VRTX

Vertex Pharmaceuticals Incorporated (VRTX) Stock Is Too Expensive

By Marie Brodbeck, InvestorPlace Contributor
VRTX stock is overpriced at the current levels. Vertex’s future holds potential, but there are quite a few possible roadblocks.

Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn’t Worth the Risk

By Josh Enomoto, InvestorPlace Contributor
Vertex Pharmaceuticals is backed by incredible scientific innovations, but VRTX stock is still a gamble on a single, flagship treatment plan.

Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher

By Dana Blankenhorn, InvestorPlace Contributor
Vertex Pharmaceuticals (VRTX) is on its way to becoming the Gilead of cystic fibrosis, which could mean solid gains for VRTX stock.

Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons

By Ian Bezek, InvestorPlace Contributor
Vertex continues to extend its dominance within cystic fibrosis treatments. But has VRTX stock run ahead of the company's potential?

Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock Like Its 20% Gain Never Happened

By Nicolas Chahine, InvestorPlace Contributor
Chasing a 20% spike in Vertex Pharma (VRTX) may seem reckless, but the options market is the closest thing to a time machine in VRTX stock.

3 Stocks to Watch on Wednesday: Vertex Pharmaceuticals Incorporated (VRTX), CSX Corporation (CSX) and International Business Machines Corp. (IBM)

By Karl Utermohlen, InvestorPlace Writer
Vertex Pharmaceuticals (VRTX) soars on cystic fibrosis treatment data, CSX Corporation (CSX) falls on a restructuring charge and International Business Machines (IBM) refuses to grow.

Wall Street’s 5 Hottest Biotech Stocks Right Now

By Harriet Lefton, Writer, TipRanks
These five top biotech stocks have the seal of approval from the Street, with 'strong buy' analyst consensus ratings and big upside.

The 10 Best S&P 500 Stocks Through 2017’s First Half

By Richard Saintvilus, InvestorPlace Contributor
The 10 best S&P 500 stocks through the first six months of 2017 are a diverse bunch that span six of the index's 10 sectors.

Will Oil Prices Spoil Tesla Inc’s (TSLA) Model 3 Party?

By Brian Wu, InvestorPlace Contributor
TSLA stock has cruised for months to all-time highs, but some fear that oil's lack of momentum could cramp Tesla's upcoming EV launch.

The 10 Worst Stocks for 2017’s Second Half

By Will Ashworth, InvestorPlace Contributor
Stocks face an uphill battle as we move into the second half of 2017 and these ten could be the worst stocks for the rest of the year.

The SPDR S&P Biotech (ETF) (XBI) Is on Breakout Watch

By Tyler Craig, Tales of a Technician
Biotech stocks are quietly climbing higher. Here's how to trade the SPDR S&P Biotech (ETF) (XBI) before its seemingly imminent pop.

The 5 Most Vulnerable Stocks in the Market Right Now

By James Brumley, InvestorPlace Feature Writer
Today's correction has been brewing for a while, and these five stocks to sell are tethered to the market selloff in the worst way.

The 3 Best Comeback Stocks to Buy in 2017

By Josh Enomoto, InvestorPlace Contributor
These companies were once dodging bullets from angry investors, but are now considered the best comeback stocks to buy.

The 10 Best Stocks of the S&P 500 in Q1

By Jeff Reeves
While the markets have been performing well in general for the first quarter, some of the S&P 500's best stocks have really cut loose.

3 Stocks to Watch on Wednesday: RH (RH), Vertex Pharmaceuticals Incorporated (VRTX) and Ollie’s Bargain Outlet Holdings Inc (OLLI)

By Karl Utermohlen, InvestorPlace Writer
RH (RH) and Ollie's Bargain Outlet (OLLI) are headed higher on earnings, while Vertex Pharmaceuticals (VRTX) is rocketing on trial results.

7 Healthcare Stocks That Will Cripple Your Portfolio

By Louis Navellier, Editor, Growth Investor
Healthcare is undergoing significant transition, so avoid the weakest ones that are prone to downside risk under the incoming administration.

Why Celgene Corporation (CELG), Nu Skin Enterprises, Inc. (NUS) and Pioneer Energy Services Corp (PES) Are 3 of Today’s Worst Stocks

By James Brumley, InvestorPlace Feature Writer
Celgene (CELG), Pioneer Energy ServiceS (PES) and Nu Skin Enterprises (NUS) couldn't win for losing on this week's hump-day.

5 Stocks to Sell for November

By Dan Burrows, InvestorPlace Feature Writer
These stocks to sell feature ugly charts and fare poorly around this time of year. If you're trying to boost November performance, jump ship.

23 Biotechnology Stocks to Sell Now

By Portfolio Grader
This week, the ratings of 23 Biotechnology stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Load More